Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • NATCO receives approval for Carfilzomib Vials ANDA in the US market

    Natco Pharma Limited is pleased to announce that its marketing partner, Breckenridge Pharmaceutical Inc. (BPI), has received approval for its Abbreviated New Drug Application (ANDA) for Carfilzomib Vials ANDA (generic for KYPROLIS), from the U.S. Food and Drug Administration (USFDA).

  • New Study Investigates the Impact of ORi-Guided Oxygen Titration on Hyperoxemia-Mediated Morbidity During One-Lung Ventilation

    Masimo announced the findings of a study published in the Turkish Journal of Medical Sciences in which Dr. Ayten Saracoglu and colleagues at the Marmara University Pendik Training and Research Hospital in Istanbul evaluated the ability of ORi to guide oxygenation by measuring its impact on hyperoxemia-mediated morbidity during one-lung ventilation conducted as part of thoracic surgery. They concluded that ORi-guided oxygen titration may reduce hospital stay and increase patient safety.

  • Indian Pharmaceutical industry affected by counterfeiting challenges

    Indian Pharmaceutical industry amongst five sectors affected by counterfeiting Incidents reported by Authentication Solution Providers Association, ASPA. There was a sharp spike in crimes related to illicit liquor, smuggling of tobacco products and pharmaceutical products especially PPE kits and sanitizers, etc during the COVID-19 lockdown.

  • FDA Grants Accelerated Approval for Alzheimer’s Drug

    The U.S. Food and Drug Administration approved Aduhelm for the treatment of Alzheimers, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

  • Senolytics reduce COVID-19 symptoms in preclinical studies

    Mayo Clinic researchers and colleagues at the University of Minnesota showed that COVID-19 exacerbates the damaging impact of senescent cells in the body. In preclinical studies, the senolytic drugs discovered at Mayo significantly reduced inflammation, illness, and mortality from COVID infection in older mice. The findings appear in the journal Science.

  • Cholesterol metabolite induces production of cancer-promoting vesicles

    Scientists working to understand the cellular processes linking high cholesterol to breast cancer recurrence and metastasis report that a byproduct of cholesterol metabolism causes some cells to send out cancer-promoting signals to other cells. These signals are packaged in membrane-bound compartments called extracellular vesicles.

    Reported in the journal Endocrinology, the discovery could lead to the development of new anti-cancer therapies, researchers say.

  • Abbott Receives European and Canadian approval for Amplatzer

    Abbott announced it has received CE Mark and Health Canada approval for its Amplatzer™ Steerable Delivery Sheath, which is used with the company's market-leading Amplatzer Amulet™ Left Atrial Appendage (LAA) Occluder. Now available in Europe and Canada, the new device is the first steerable delivery sheath that has been developed specifically for minimally invasive LAA occlusion (or closure) procedures to treat patients diagnosed with atrial fibrillation who are at risk of ischemic stroke.

  • Indo Irish Biotech Startup CyGenica Secures Funding for Cancer and Rare Genetic Disease Therapy

    CyGenica has announced that it has raised USD 1.4 million in a seed fund investment round, led by global venture capital investor SOSV. The funding round will accelerate validation of CyGenica’s proprietary technology which enables safe, targeted, and affordable intercellular drug delivery.

    CyGenica’s disruptive technology addresses the problem of delivering large-molecule therapeutics into living cells without damaging them or triggering an adverse immune response.

  • No data to show children will be seriously infected in next COVID-19 waves : Dr. Randeep Guleria

    “It is a piece of misinformation that subsequent waves of the COVID-19 pandemic are going to cause severe illness in children. There is no data - either from India or globally - to show that children will be seriously infected in subsequent waves.” This was informed by Director, All India Institute of Medical Sciences (AIIMS) Delhi, Dr. Randeep Guleria, during a media briefing on COVID-19, held at National Media Centre, PIB Delhi today.

  • One step closer to stem cell therapy for type 1 diabetes : Researcher

    Type 1 diabetes, which arises when the pancreas doesn’t create enough insulin to control levels of glucose in the blood, is a disease that currently has no cure and is difficult for most patients to manage. Scientists at the Salk Institute are developing a promising approach for treating it: using stem cells to create insulin-producing cells (called beta cells) that could replace nonfunctional pancreatic cells.

Subscribe to Pharma News